| BACE-2 in complex with ligand 36 | |
Heteromer
| 75-460 | 100.0 | 1×0BK; 4×EDO; |
|
| BACE2 XAPERONE COMPLEX | |
Heteromer
| 75-460 | 100.0 | 1×B3P; 1×CL; |
|
| BACE2 xaperone complex with N-{3-[(5R)-3-amino-5-methyl-9,9-dioxo-2,9lambda6-dithia-4-azaspiro[5.5]… | |
Heteromer
| 75-460 | 100.0 | 1×C7O; 1×CL; |
|
| BACE2 xaperone complex with N-{3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-5,6-dihydro-2H-1lambda6,2,4-t… | |
Heteromer
| 75-459 | 100.0 | 1×66F; 1×CL; 3×EDO; 2×NA; |
|
| BACE2 xaperone complex with N-{3-[(4R,5R,6R)-2-amino-5-fluoro-4,6-dimethyl-5,6-dihydro-4H-1,3-thiaz… | |
Heteromer
| 75-459 | 100.0 | 1×0QQ; |
|
| BACE2 XAPERONE COMPLEX WITH INHIBITOR | |
Heteromer
| 75-459 | 100.0 | 1×WZV; |
|
| BACE2 XAPERONE COMPLEX | |
Heteromer
| 76-459 | 100.0 | 1×CL; 1×B3P; |
|
| BACE2 FAB COMPLEX | |
Heteromer
| 76-459 | 100.0 | 1×SO4; 1×DMS; 1×GOL; |
|
| BACE2 FAB INHIBITOR COMPLEX | |
Heteromer
| 76-459 | 100.0 | 1×WZV; 1×DMS; 3×SO4; 1×GOL; |
|
| BACE2 xaperone complex with N-{3-[(9S)-7-amino-2,2-difluoro-9-(prop-1-yn-1-yl)-6-oxa-8-azaspiro[3.5… | |
Heteromer
| 77-459 | 100.0 | 1×GX6; |
|
| BACE2 XAPERONE COMPLEX | |
Heteromer
| 77-459 | 100.0 | 2×6T9; |
|
| BACE2 XAPERONE COMPLEX | |
Heteromer
| 77-459 | 100.0 | |
|
| TERNARY BACE2 XAPERONE COMPLEX | |
Heteromer
| 78-459 | 99.73 | 1×CL; 1×DMS; |
|
| BACE2 FYNOMER COMPLEX | |
Heteromer
| 78-459 | 100.0 | |
|
| BACE2 MUTANT APO STRUCTURE | | monomer | 76-459 | 100.0 | 1×B3P; |
|
| BACE2 MUTANT STRUCTURE WITH LIGAND | | monomer | 76-459 | 100.0 | 1×WZV; |
|
| Crystal structure of human BACE2 in complex with a hydroxyethylenamine transition-state inhibitor | | monomer | 78-460 | 100.0 | 1×DBO; |
|
| BACE2 mutant in complex with a macrocyclic compound | | monomer | 78-459 | 100.0 | 1×L3M; |
|
| Unbound BACE2 mutant structure | | monomer | 79-459 | 99.73 | |
|